Investor's Business Daily
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
📈
AI Sentiment
Highly Positive
8/10
Regeneron Pharmaceuticals Inc. News
Latest updates and market news for REGN
9 news
Dec 4 - Dec 10, 2025
Page 1
GlobeNewswire
Lynozyficâ„¢ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Does Regeneron’s Choppy 2025 Share Price Reflect Its Long Term Growth Potential?
📊
AI Sentiment
Positive
7/10
Zacks
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
📈
AI Sentiment
Highly Positive
8/10
Zacks
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
âž–
AI Sentiment
Neutral
4/10
MT Newswires
BMO Capital Adjusts PT on Regeneron Pharmaceuticals to $850 From $725, Maintains Outperform Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
Share this news page